Can upfront DPYD extended variant testing reduce toxicity and associated hospital costs of fluoropyrimidine chemotherapy? A propensity score matched analysis of 2022 UK patients

Abstract Aim To independently assess the impact of mandatory testing using an extended DPYD variant panel (ToxNav®) and consequent dose adjustment of Capecitabine/5-FU on recorded quantitative toxicity, symptoms of depression, and hospital costs. Methods We used propensity score matching (PSM) to ma...

Disgrifiad llawn

Wedi'i Gadw mewn:
Manylion Llyfryddiaeth
Prif Awduron: Apostolos Tsiachristas, Grant Vallance, Rositsa Koleva-Kolarova, Harriet Taylor, Luke Solomons, Giovanni Rizzo, Catherine Chaytor, Junel Miah, Sarah Wordsworth, A. Bassim Hassan
Fformat: Artigo
Iaith:Inglês
Cyhoeddwyd: BMC 2022-04-01
Cyfres:BMC Cancer
Mynediad Ar-lein:https://doi.org/10.1186/s12885-022-09576-3
Tagiau: Ychwanegu Tag
Dim Tagiau, Byddwch y cyntaf i dagio'r cofnod hwn!

Eitemau Tebyg